Many studies have shown that EZH2 overexpression is correlated with human hematological malignancies, and EZH2 has been established as a critical target for hematological cancers (Abd Al Kader et al., 2013; van Galen et al., 2007; Yan et al., 2013). Here, EZH2 is linked to hematologic disorder.